Blockchain Registration Transaction Record

HeartBeam's 12-Lead ECG Software Nears FDA Clearance in Q3 2025

HeartBeam advances 12-lead ECG software toward FDA clearance, partners with HeartNexus for cardiologist review. Revolutionary portable cardiac monitoring technology transforms remote heart care.

This development matters because it represents a fundamental shift in cardiac care accessibility. Traditional 12-lead ECGs require bulky equipment and clinical settings, limiting timely detection of heart conditions. HeartBeam's portable, cable-free technology enables remote monitoring and early intervention for conditions like heart attacks and arrhythmias, potentially saving lives by allowing immediate cardiac assessment anywhere. For the millions at risk of cardiovascular disease, this technology could mean faster diagnosis, reduced hospital visits, and more proactive heart health management. The FDA clearance would validate a new standard in telemedicine and remote patient monitoring, addressing critical gaps in current cardiac care infrastructure.